BioSpace News Archive

Atomwise , the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launc

Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2019. “We’re pleased to close out another year of compelling growth, product launches, productive capital raises, key hires and technology adoption, mark

FEP® to eliminate restrictions on prescription drug refills, waive pre-authorization, deductibles and copays for diagnostics, treatment

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company’s Chief Financial Officer, will hold a virtual presentation at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020 at 1:35 PM ET. The live and archived webcast of the presentation will be accessible from the

Lack of sleep from daylight savings time affects productivity, work performance, concentration, and memory, according to physicians at the University of Washington.

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of recently obtained top-line data from the Phase 2a AVANTE clinical study. The Phase 2a AVANTE clinical study is a rando